• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zosano Pharma Corporation

    5/18/22 9:16:15 AM ET
    $ZSAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZSAN alert in real time by email
    SC 13G 1 ea160197-13gfive_zosano.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. ___)

     

    ZOSANO PHARMA CORPORATION

     

    (Name of Issuer)

     

    COMMON STOCK, $0.0001 PAR VALUE PER SHARE

     

    (Title of Class of Securities)

     

    98979H301

     

    (CUSIP Number)

     

    May 11, 2022

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s)

     

     

     

    Page 1 of 5 Pages

     

     

    CUSIP No. 98979H301   13G   Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Five Narrow Lane LP 

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

    (a) ☐

    (b) ☐

     

    3. SEC USE ONLY

     

     

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New York 

     

    5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 262,177 Shares of Common Stock (1)

     

     

    6. SHARED VOTING POWER - None

     

     

     

    7. SOLE DISPOSITIVE POWER – 262,177 Shares of Common Stock (1)

     

     

     

    8. SHARED DISPOSITIVE POWER – None

     

     

     

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON - 262,177 Shares of Common Stock (1)

     

     

     

    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

     

     

    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.348% (1)

     

    12. TYPE OF REPORTING PERSON

     

    OO

     

     

    (1)Based on 4,902,260 shares outstanding as of May 11, 2022 as reported on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2022.

     

     

     

     

    CUSIP No. 98979H301   13G   Page 3 of 5 Pages

     

    ITEM 1 (a) NAME OF ISSUER: Zosano Pharma Corporation, a Delaware corporation

     

    ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

     

    34790 Ardentech Court, Fremont, CA 94555

     

    ITEM 2 (a) NAME OF PERSON FILING: Five Narrow Lane LP

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    510 Madison Avenue, Suite 1400, New York, NY 10022

     

    ITEM 2 (c) CITIZENSHIP: New York

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $0.0001 par value per share

     

    ITEM 2 (e) CUSIP NUMBER: 98979H301

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4 OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 262,177 Shares of Common Stock (1)

     

    (b) PERCENT OF CLASS: 5.348% (1)

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    262,177 Shares of Common Stock (1)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    262,177 Shares of Common Stock (1)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

     

    CUSIP No. 98979H301   13G   Page 4 of 5 Pages

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9 NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      May 17, 2022
      (Date)
       
      /s/ Arie Rabinowitz
      (Signature)
       
      Arie Rabinowitz, Partner
      (Name/Title)

     

     

    Page 5 of 5 Pages

     

     

    Get the next $ZSAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZSAN

    DatePrice TargetRatingAnalyst
    2/23/2022Buy → Neutral
    BTIG
    More analyst ratings

    $ZSAN
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Zosano Pharma Corporation

      25-NSE - Zosano Pharma Corp (0001587221) (Subject)

      7/19/22 11:47:51 AM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zosano Pharma Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Zosano Pharma Corp (0001587221) (Filer)

      6/3/22 8:01:04 AM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zosano Pharma Corporation filed SEC Form 8-K: Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - Zosano Pharma Corp (0001587221) (Filer)

      6/2/22 8:35:55 AM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZSAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Matthews Christine sold $58 worth of shares (82 units at $0.71), decreasing direct ownership by 2% to 4,183 units to satisfy withholding obligation

      4 - Zosano Pharma Corp (0001587221) (Issuer)

      6/7/22 7:39:15 PM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lo Steven sold $314 worth of shares (442 units at $0.71), decreasing direct ownership by 3% to 13,163 units (withholding obligation)

      4 - Zosano Pharma Corp (0001587221) (Issuer)

      6/7/22 7:37:48 PM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Matthews Christine sold $1,705 worth of shares (8,116 units at $0.21), decreasing direct ownership by 5% to 146,425 units (withholding tax)

      4 - Zosano Pharma Corp (0001587221) (Issuer)

      4/1/22 9:09:16 PM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZSAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

      FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 ("Chapter 11") of the United States Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"), thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a "debtor-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. Zosano

      6/2/22 8:00:00 AM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma's Micro-Needle Patch

      PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma's Micro-Needle Patch Emergex's COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex', or the ‘Company'), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation's (NASDAQ:ZSAN) proprietary microneedle patch system. Zosano's patch consists of

      5/17/22 7:00:00 AM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zosano Pharma Reports First Quarter 2022 Financial Results

      FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared with a net loss of $8.1 million, or $2.73 per share on a basic and diluted basis, for the same quarter in 2021. Research and development expenses for the first quar

      5/13/22 4:00:00 PM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZSAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zosano Pharma downgraded by BTIG

      BTIG downgraded Zosano Pharma from Buy to Neutral

      2/23/22 6:16:45 AM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group reiterated coverage on Zosano Pharma with a new price target

      Maxim Group reiterated coverage of Zosano Pharma with a rating of Buy and set a new price target of $2.50 from $1.50 previously

      3/15/21 12:17:36 PM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZSAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zosano Pharma Corporation

      SC 13G - Zosano Pharma Corp (0001587221) (Subject)

      5/18/22 9:16:15 AM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZSAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang

      FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. "We are pleased to welcome Elaine, a high caliber executive, to our board of directors," said Steven Lo, president and chief executive officer of Zosano. "Elaine has deep and broad executive leadership experience, building and running cross functional departments, including business operations functions for companies with fast growth trajectories such as Genentech and Facebook, and her experience will be valuable to Zosano as we plan for success." Elaine M

      12/13/21 4:30:00 PM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors

      FREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience from a broad range of leadership roles across operations, strategic planning, manufacturing and supply chain management, quality and regulatory affairs and new product development. "Kathy is an exceptional addition to the board, bringing deep experience across many functional areas, and we are thrilled to have her join our board," said Steven Lo, president and chief executive officer of Zosano. "As we work to

      5/25/21 4:05:00 PM ET
      $ZSAN
      Biotechnology: Pharmaceutical Preparations
      Health Care